¶ LATE (Limbic-Predominant Age-Related TDP-43 Encephalopathy)
¶ Introduction
Late (Limbic Predominant Age Related Tdp 43 Encephalopathy) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
¶ Overview
Limbic-predominant age-related [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- encephalopathy (LATE) is a recently recognized neurodegenerative condition defined by the
accumulation of pathological [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- protein deposits primarily in limbic brain structures, including the amygdala, [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, and
entorhinal/inferior temporal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/cortex--TEMP--/brain-regions)--FIX--. First formally defined by an international consensus working group in 2019, LATE neuropathologic
change (LATE-NC) is detectable at autopsy in more than one-third of individuals beyond age 85, making it one of the most prevalent
neurodegenerative pathologies in the oldest-old population [[1])].
LATE presents clinically as a slowly progressive amnestic syndrome resembling [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, and frequently co-occurs with
[Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/alzheimers--TEMP--/diseases)--FIX-- neuropathologic change (ADNC). In community-based autopsy cohorts, approximately 25% of brains have sufficient LATE-NC
burden to be associated with discernible cognitive impairment. Critically, in the oldest-old (>90 years at death), the impact of LATE-NC on
dementia rivals or exceeds that of Alzheimer's pathology, underscoring its importance as an independent driver of late-life cognitive
decline [[2]].
¶ Neuropathologic Change (LATE-NC)
¶ Definition
LATE-NC is defined by the presence of [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- proteinopathy] in a stereotypical limbic-predominant distribution, with or without coexisting
hippocampal sclerosis. The pathological [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- inclusions in LATE are distinct from those seen in [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--/[FTD[/diseases/[ftd[/diseases/[ftd[/diseases/ftd--TEMP--/diseases)--FIX--: they tend to be neuronal
cytoplasmic inclusions and dystrophic neurites primarily involving limbic structures, rather than the motor system [[3])].
¶ Staging
The consensus working group proposed a three-stage system for grading LATE-NC severity based on the anatomical distribution of [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology:
| Stage | Affected Regions | Clinical Correlation |
|---|---|---|
| Stage 1 | Amygdala only | Often subclinical; may contribute to emotional/behavioral changes |
| Stage 2 | Amygdala + [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- | Associated with memory impairment and hippocampal atrophy |
| Stage 3 | Amygdala + [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- + middle frontal gyrus | Associated with more severe cognitive impairment and broader cortical involvement |
Higher LATE-NC stages correlate with greater hippocampal atrophy on neuroimaging and more severe cognitive impairment [[1])]](https://https
/academic.oup.com/brain/article/142/6/1503/5481202).
¶ Hippocampal Sclerosis
Hippocampal sclerosis of aging (HS-A) is characterized by profound loss of pyramidal [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and associated gliosis in the CA1 subfield
and subiculum of the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--. HS-A is present in 60–95% of LATE-NC cases and significantly amplifies the cognitive impact of LATE-NC.
Cases with LATE-NC plus HS-A but lacking ADNC represent a distinct "pure LATE" subtype in which [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/tdp-43--TEMP--/entities)--FIX---related mechanisms are likely the
primary drivers of hippocampal neuronal loss [[4])].
The relationship between [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- proteinopathy and hippocampal sclerosis is thought to be causal: [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- dysfunction leads to neuronal death in vulnerable hippocampal subfields, producing the pattern of selective neuronal loss characteristic of HS-A.
¶ Epidemiology
¶ Prevalence
LATE-NC is remarkably common in advanced age:
- Age 65–79: ~15% prevalence at autopsy
- Age 80–89: ~25% prevalence
- Age 90+: ~40% prevalence
- Among centenarians, LATE-NC is nearly ubiquitous
In large autopsy cohort studies, LATE-NC is the third most common neurodegenerative pathology (after ADNC and Lewy body pathology) and has a stronger association with dementia than many other age-related pathologies [[2]].
¶ Risk Factors
Age: The strongest risk factor; prevalence increases exponentially after age 80.
Genetic risk factors: Several low-penetrance genetic variants have been identified:
- TMEM106B: The strongest genetic risk factor for LATE-NC; variants at the TMEM106B locus increase susceptibility to [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- proteinopathy. TMEM106B encodes a lysosomal transmembrane protein
- [GRN[/genes/[grn[/genes/[grn[/genes/[grn--TEMP--/genes)--FIX-- (progranulin): Common variants reducing progranulin levels increase LATE-NC risk, paralleling the role of GRN mutations in [FTLD-TDP]
- [APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX--/entities/apoe: The [APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX--.
Vascular risk factors: Cerebrovascular disease, arteriolosclerosis, and [Blood-Brain Barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- dysfunction may contribute to LATE-NC vulnerability.
¶ Clinical Features
¶ Cognitive Profile
LATE presents as a slowly progressive amnestic syndrome with features that overlap substantially with [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--:
- Prominent episodic memory impairment disproportionate to other cognitive domains
- Slower rate of progression compared to typical [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- when LATE-NC is the sole pathology
- More rapid progression when LATE-NC co-occurs with ADNC compared to ADNC alone
- Relative preservation of visuospatial and executive function early in the course
When LATE-NC co-occurs with Alzheimer's pathology (which is common), the clinical trajectory is accelerated, with earlier conversion to dementia and faster decline [6].
¶ Clinical Criteria (2025)
In 2025, the first clinical diagnostic criteria for LATE were proposed, enabling in-vivo identification:
Probable LATE (amyloid-negative):
- Progressive memory impairment
- Substantial hippocampal atrophy on MRI
- Negative amyloid biomarkers (amyloid-PET or CSF)
- Age typically >75 years
Possible LATE (amyloid status unknown or positive):
- Progressive memory impairment with disproportionate hippocampal atrophy
- When amyloid biomarkers are unavailable, or when [amyloid] co-pathology is present
- Ratio of medial temporal to inferior temporal atrophy/hypometabolism suggestive of LATE-NC [7]
¶ Neuroimaging Biomarkers
- MRI: Disproportionate hippocampal and medial temporal lobe atrophy relative to the severity of amyloid or tau] pathology
- FDG-PET: Hypometabolism in the medial temporal lobe and orbitofrontal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- with relatively preserved inferior temporal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--; the ratio of inferior to medial temporal metabolism is elevated in LATE-NC cases with useful sensitivity and specificity
- [Amyloid-PET[/entities/[amyloid-pet[/entities/[amyloid-pet[/entities/[amyloid-pet--TEMP--/entities)--FIX--: Negative in "pure" LATE cases; when positive, indicates co-occurring ADNC
- **[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/p-tau217--TEMP--/entities)--FIX-- and other AD biomarkers**: Typically not elevated in pure LATE, helping differentiate from Alzheimer's Disease [[2]]
¶ Co-Pathologies
LATE-NC frequently coexists with other neurodegenerative and vascular pathologies:
- Alzheimer's Disease neuropathologic change (ADNC): The most common co-pathology; LATE-NC + ADNC is associated with more severe cognitive impairment and faster decline than either alone
- Brain arteriolosclerosis: Small vessel disease frequently co-occurs with LATE-NC and may contribute to its pathogenesis
- Age-related tau] astrogliopathy (ARTAG): [Astrocytic] tau] pathology often co-occurs in regions affected by LATE-NC
- Lewy body pathology: [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--
¶ Pathophysiology
The mechanisms underlying LATE-NC are not fully understood, but several pathways have been implicated:
¶ TDP-43 Mislocalization and Aggregation
The core pathological event is the mislocalization of [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- from the nucleus to the cytoplasm in affected [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, followed by aggregation, phosphorylation, ubiquitination, and C-terminal fragmentation. This results in both:
- Loss of nuclear [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- function: Including failure to repress cryptic exons in STMN2 and UNC13A, disruption of RNA splicing, and retrotransposon de-repression (see [TDP-43 Proteinopathy)
- Cytoplasmic toxicity: From aggregated [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/tdp-43--TEMP--/entities)--FIX-- and its C-terminal fragments [[3])]
¶ Lysosomal Dysfunction
The strong genetic association with TMEM106B (a lysosomal protein) suggests that impaired lysosomal function and autophagy may be a central mechanism in LATE-NC pathogenesis, potentially affecting [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/tdp-43--TEMP--/entities)--FIX-- clearance and contributing to its accumulation [[4])].
¶ Vascular Contributions
Arteriolosclerosis and Blood-Brain Barrier dysfunction frequently accompany LATE-NC, suggesting that vascular injury may create a permissive environment for [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- proteinopathy in vulnerable limbic structures.
¶ Aging-Related Vulnerability
The extreme age-dependence of LATE-NC suggests that age-related cellular changes—including declining proteostasis, accumulating oxidative damage, [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--, and cellular senescence—converge to promote [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- mislocalization and aggregation in limbic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--.
¶ Differential Diagnosis
LATE must be distinguished from other causes of amnestic cognitive decline:
| Condition | Distinguishing Features |
|---|---|
| [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- | Positive amyloid and tau] biomarkers; cortical > hippocampal atrophy ratio |
| [Vascular Dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia--TEMP--/diseases)--FIX-- | Stepwise decline; prominent white matter changes; vascular risk factors |
| [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX-- | Visual hallucinations; parkinsonism; fluctuating cognition |
| [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- | Behavioral/language changes; younger onset; frontal/temporal atrophy |
| Depressive pseudodementia | Reversible; history of depression; subjective complaints > objective deficits |
¶ Therapeutic Implications
Currently, there are no specific therapies for LATE. However, its recognition has important clinical implications:
- Clinical trial design: Patients with LATE-NC may be enrolled in Alzheimer's trials and may not respond to amyloid-targeting therapies such as [lecanemab[/treatments/[lecanemab[/treatments/[lecanemab[/treatments/[lecanemab--TEMP--/treatments)--FIX-- or [donanemab[/treatments/[donanemab[/treatments/[donanemab[/treatments/[donanemab--TEMP--/treatments)--FIX--, potentially diluting trial efficacy signals
- Biomarker-guided diagnosis: The development of [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX---specific biomarkers would enable proper patient stratification and targeted therapy development
- Emerging therapeutic targets: Strategies targeting [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- aggregation, [autophagy enhancement], lysosomal function (via TMEM106B pathways), and cryptic exon correction may be relevant to LATE as well as ALS/FTD
- Precision medicine: Distinguishing LATE from AD enables appropriate prognostication and avoidance of ineffective treatments [8]
¶ See Also
- [Apolipoprotein E ([APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX--/entities/apoe(https://brain-map.org/) - Brain gene expression data
¶ Background
The study of Late (Limbic Predominant Age Related Tdp 43 Encephalopathy) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ External Links
- PubMed - Biomedical literature
- Alzheimer's Disease Neuroimaging Initiative - Research data
- Allen Brain Atlas - Brain gene expression data
¶ References
- [Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE]: consensus working group report. Brain. 2019;142(6):1503-1527. Brain)
- [Katsumata Y, Fardo DW, Kukull WA, Nelson PT. Limbic-predominant age-related [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- encephalopathy: LATE-breaking updates in clinicopathologic features and biomarkers. Curr Neurol Neurosci Rep. 2022. PMC9633415)
- [Nag S, Yu L, Wilson RS, et al. Limbic-predominant age-related TDP43 encephalopathy (LATE] neuropathological change in neurodegenerative diseases. Nat Rev Neurol. 2023. Nature)
- [Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE-NC]: Co-pathologies and genetic risk factors provide clues about pathogenesis. J Neuropathol Exp Neurol. 2024;83(6):396-415. JNEN)
- [Dugan AJ, et al. Genome-wide association studies of [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- proteinopathy and hippocampal sclerosis reveal shared genetic associations with [APOE and TMEM106B. Acta Neuropathol. 2025. [PMC12598407)https://pmc.ncbi.nlm.nih.gov/articles/PMC12598407/)
- [Besser LM, et al. Cognitive and clinical characteristics of patients with LATE. Neurology. 2024. Neurology)
- [Wolk DA, et al. Clinical criteria for limbic-predominant age-related [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- encephalopathy. Alzheimers Dement. 2025. Wiley)
- [Corriveau-Lecavalier N, et al. Limbic-predominant age-related [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- encephalopathy. Neurology. 2023. Neurology)